Reboxetine (mesylate)

• UNSPSC Description:

  Reboxetine mesylate (FCE20124 mesylate) is a potent, selective, and specific noradrenaline reuptake inhibitor (NARI) for the research of depression. Reboxetine mesylate inhibits the uptake of norepinephrine, with a Ki of 8 nM[1].

• Target Antigen:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/reboxetine-mesylate.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  CS(=O)(O)=O.CCOC1=C(C=CC=C1)O[C@]([C@@]2([H])CNCCO2)([H])C3=CC=CC=C3

• Molecular Weight:

  409.50

• References & Citations:

  [1]Wong, E.H., et al., Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry, 2000. 47(9): p. 818-29.|[2]Versiani, M., et al., Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry, 1999. 60(6): p. 400-6.|[3]M Leskiewicz, et al. Antidepressants attenuate the dexamethasone-induced decrease in viability and proliferation of human neuroblastoma SH-SY5Y cells: a involvement of extracellular regulated kinase (ERK1/2). Neurochem Int. 2013 Nov;63(5):354-62.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  98769-84-7